Connection

Sharon Yeatts to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Sharon Yeatts has written about Treatment Outcome.
Sharon Yeatts
Connection Strength
0.665
Treatment Outcome
  1. Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design. Int J Stroke. 2018 08; 13(6):654-661.
    View in: PubMed
    Score: 0.066
  2. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
    View in: PubMed
    Score: 0.050
  3. Novel methodologic approaches to phase I, II, and III trials. Stroke. 2013 Jun; 44(6 Suppl 1):S116-8.
    View in: PubMed
    Score: 0.047
  4. Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 07; 53(7):2204-2210.
    View in: PubMed
    Score: 0.022
  5. National Institutes of Health Stroke Scale as an Outcome in Stroke Research: Value of ANCOVA Over Analyzing Change From Baseline. Stroke. 2022 04; 53(4):e150-e155.
    View in: PubMed
    Score: 0.022
  6. Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 04; 53(4):1149-1156.
    View in: PubMed
    Score: 0.021
  7. Predicting 90-Day Outcome After Thrombectomy: Baseline-Adjusted 24-Hour NIHSS Is More Powerful Than NIHSS Score Change. Stroke. 2021 08; 52(8):2547-2553.
    View in: PubMed
    Score: 0.021
  8. Computer-Assisted Measurement of Traumatic Brain Hemorrhage Volume Is More Predictive of Functional Outcome and Mortality than Standard ABC/2 Method: An Analysis of Computed Tomography Imaging Data from the Progesterone for Traumatic Brain Injury Experimental Clinical Treatment Phase-III Trial. J Neurotrauma. 2021 03; 38(5):604-615.
    View in: PubMed
    Score: 0.020
  9. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? J Stroke Cerebrovasc Dis. 2019 Nov; 28(11):104371.
    View in: PubMed
    Score: 0.018
  10. Association of Very Early Serum Levels of S100B, Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and Spectrin Breakdown Product with Outcome in ProTECT III. J Neurotrauma. 2019 10 15; 36(20):2863-2871.
    View in: PubMed
    Score: 0.018
  11. Association of Thrombectomy With Stroke Outcomes Among Patient Subgroups: Secondary Analyses of the DEFUSE 3 Randomized Clinical Trial. JAMA Neurol. 2019 04 01; 76(4):447-453.
    View in: PubMed
    Score: 0.018
  12. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 05; 18(5):428-438.
    View in: PubMed
    Score: 0.018
  13. Endovascular Treatment in the DEFUSE 3 Study. Stroke. 2018 08; 49(8):2000-2003.
    View in: PubMed
    Score: 0.017
  14. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA. 2018 07 10; 320(2):156-166.
    View in: PubMed
    Score: 0.017
  15. Prehospital Intubation is Associated with Favorable Outcomes and Lower Mortality in ProTECT III. Prehosp Emerg Care. 2017 Sep-Oct; 21(5):539-544.
    View in: PubMed
    Score: 0.016
  16. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
    View in: PubMed
    Score: 0.016
  17. Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trials. BMJ. 2017 May 03; 357:j1710.
    View in: PubMed
    Score: 0.016
  18. A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3). Int J Stroke. 2017 10; 12(8):896-905.
    View in: PubMed
    Score: 0.015
  19. Towards personalised intra-arterial treatment of patients with acute ischaemic stroke: a study protocol for development and validation of a clinical decision aid. BMJ Open. 2017 03 22; 7(3):e013699.
    View in: PubMed
    Score: 0.015
  20. ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2. Stroke. 2016 09; 47(9):2355-9.
    View in: PubMed
    Score: 0.015
  21. Very Early Administration of Progesterone Does Not Improve Neuropsychological Outcomes in Subjects with Moderate to Severe Traumatic Brain Injury. J Neurotrauma. 2017 01 01; 34(1):115-120.
    View in: PubMed
    Score: 0.014
  22. Effect of endovascular reperfusion in relation to site of arterial occlusion. Neurology. 2016 Feb 23; 86(8):762-70.
    View in: PubMed
    Score: 0.014
  23. Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial. Stroke. 2015 Aug; 46(8):2142-8.
    View in: PubMed
    Score: 0.014
  24. Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis. Stroke. 2015 Aug; 46(8):2325-7.
    View in: PubMed
    Score: 0.014
  25. Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
    View in: PubMed
    Score: 0.013
  26. Differential Effect of Baseline Computed Tomographic Angiography Collaterals on Clinical Outcome in Patients Enrolled in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1239-44.
    View in: PubMed
    Score: 0.013
  27. Early reperfusion and clinical outcomes in patients with M2 occlusion: pooled analysis of the PROACT II, IMS, and IMS II studies. J Neurosurg. 2014 Dec; 121(6):1354-8.
    View in: PubMed
    Score: 0.013
  28. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014 Oct; 273(1):202-10.
    View in: PubMed
    Score: 0.013
  29. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
    View in: PubMed
    Score: 0.013
  30. Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
    View in: PubMed
    Score: 0.012
  31. Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014 Feb; 45(2):444-9.
    View in: PubMed
    Score: 0.012
  32. Impact of onset-to-reperfusion time on stroke mortality: a collaborative pooled analysis. Circulation. 2013 May 14; 127(19):1980-5.
    View in: PubMed
    Score: 0.012
  33. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
    View in: PubMed
    Score: 0.012
  34. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010 Nov; 41(11):2581-6.
    View in: PubMed
    Score: 0.010
  35. Is periprocedural sedation during acute stroke therapy associated with poorer functional outcomes? J Neurointerv Surg. 2010 Mar; 2(1):67-70.
    View in: PubMed
    Score: 0.009
  36. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009 Sep 29; 73(13):1066-72.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.